Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of rhu-pGSN in Healthy Volunteers
NCT05789745Phase 1Completed
- Sponsor
- BioAegis Therapeutics
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute respiratory distress syndrome (ARDS), pneumonia and sepsis comparing rhu-pGSN with Placebo (2 arms). Primary endpoints: Adverse Events at 28 days and Serious Adverse Events at 28 days. Started Mar 2023; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
acute respiratory distress syndrome (ARDS)pneumoniasepsis
Beyond the preview
Go deeper on NCT05789745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789745.